Fmr LLC reduced its stake in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 6.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 841,232 shares of the company’s stock after selling 57,600 shares during the quarter. Fmr LLC owned approximately 2.09% of Biohaven Pharmaceutical worth $31,109,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of BHVN. Flinton Capital Management LLC acquired a new position in shares of Biohaven Pharmaceutical during the fourth quarter worth approximately $42,000. Neuburgh Advisers LLC acquired a new position in shares of Biohaven Pharmaceutical during the fourth quarter worth approximately $52,000. Legal & General Group Plc lifted its holdings in shares of Biohaven Pharmaceutical by 14.1% during the fourth quarter. Legal & General Group Plc now owns 5,284 shares of the company’s stock worth $196,000 after buying an additional 652 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Biohaven Pharmaceutical during the third quarter worth approximately $218,000. Finally, Blueshift Asset Management LLC acquired a new position in shares of Biohaven Pharmaceutical during the fourth quarter worth approximately $306,000. Hedge funds and other institutional investors own 88.91% of the company’s stock.
In other Biohaven Pharmaceutical news, insider John Tilton sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $50.11, for a total value of $501,100.00. Following the sale, the insider now directly owns 10,000 shares in the company, valued at $501,100. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Declan Doogan sold 2,078 shares of the company’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $45.48, for a total value of $94,507.44. The disclosure for this sale can be found here. Insiders sold 437,856 shares of company stock worth $22,279,475 over the last quarter. Company insiders own 34.20% of the company’s stock.
BHVN opened at $60.16 on Monday. The company has a market cap of $2.66 billion, a PE ratio of -9.78 and a beta of 0.50. Biohaven Pharmaceutical Holding Co Ltd has a 1 year low of $25.60 and a 1 year high of $62.25.
Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Thursday, February 28th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.06). On average, analysts predict that Biohaven Pharmaceutical Holding Co Ltd will post -6.21 EPS for the current year.
Biohaven Pharmaceutical Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Recommended Story: Liquidity
Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.